TP53 and cancer: However, few studies have correlated the TP53 mutation status with cancer immunotherapy response, although a recent clinical trial (phase II) data showed that patients with mutated-p53 metastatic breast cancer had better overall survival (OS) when treated with the immunooncology viral agent REOLYSIN® in combination with paclitaxel [16].